心血管疾患の死亡率の曲線を曲げる ベセスダ + 40 以降
David Calvin Goff1, Sadiya Sana Khan2, Donald Lloyd-Jones2
1Division of Cardiovascular Sciences (D.C.G., G.S.W.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Circulation
|February 22, 2021
まとめ
冠動脈性心疾患による死亡率の減少は逆転し,心不全による死亡率は上昇しています. 1978 年 以降 の 進歩 を 振り返っ て,心血管 の 健康 を 改善 する 策 を 議論 し た シンポジウム が 開催 さ れ まし た.
科学分野:
- 心血管疾患の疫学
- 公衆衛生政策
- 予防的な心臓科
背景:
- 1978年のベセスダ会議は,冠動脈疾患 (CHD) の死亡率の減少を理解するための枠組みを提供した.
- 最近の動向は,心臓病の死亡率の減少が停滞し,または逆転し,心不全 (HF) の死亡率が増加していることを示唆しています.
- 知識と治療の進歩は,心血管疾患 (CVD) の有害な傾向を完全に止めることができませんでした.
研究 の 目的:
- 1978年のベセスダ会議の 40周年を記念して
- 1978年の会議の成果を評価し,現在のCVDの状況を評価する.
- 心血管の健康を維持し促進し,心血管疾患を予防するための機会を特定する.
主な方法:
- "心臓血管疾患の死亡率の曲線を曲げる ベセスダ+40"シンポジウムを開催しました.
- CVD,肥満,糖尿病の傾向と予測について議論しました.
- 生涯を通して心血管の健康を促進するための課題と障壁を調査した.
主要な成果:
- 総合的なCVDの死亡率は減速していますが,HFの死亡率は増加しています.
- 肥満と糖尿病の流行は 大きな課題となっています
- 早期の介入と観察研究のための枠組みが提案されました.
結論:
- 心血管疾患による死亡率は複雑で 再度注目する必要があります
- 胎児の早期の介入は 長期的な心血管の健康に不可欠です
- 肥満と糖尿病の治療は 将来のCVDの予防に不可欠です
関連する概念動画
01:29Bias in Epidemiological Studies
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...